https://www.selleckchem.com/products/ABT-888.html
Metronomic treatment is hypothesized to be less toxic and more effective as compared to standard maximal tolerable dosing treatment in metastatic cancer disease. We tested the metronomic treatment principle with vinorelbine in a randomized phase 2 setting combined with standard capecitabine treatment in the XeNa trial with Clinical Trials.gov identifier number NCT0141771. 120 patients with disseminated HER2 non-amplified breast cancer were included. Randomization was between Arm A vinorelbine 60 mg/m day 1 + day 8 in the first cycle fol
Like
Comment
Share
